Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy

CHEN-HUA LIUHSIN-YUN SUNSZU-MIN HSIEHLiu W.-C.WANG-HUEI SHENGCHUN-JEN LIUTUNG-HUNG SUTAI-CHUNG TSENGPEI-JER CHENCHIEN-CHING HUNGJIA-HORNG KAO2021-08-202021-08-2020211352-0504https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103427501&doi=10.1111%2fjvh.13502&partnerID=40&md5=98606585fcc2bf3e37c199b7a3dcb0fdhttps://scholars.lib.ntu.edu.tw/handle/123456789/578637The nephrotoxicity of sofosbuvir (SOF) on human immunodeficiency virus and hepatitis C virus (HIV/HCV)-coinfected patients receiving antiretroviral therapy (ART) remains controversial. We prospectively compared the estimated glomerular filtration rate (eG[SDGs]SDG3bictegravir plus emtricitabine plus tenofovir alafenamide; cobicistat plus elvitegravir plus emtricitabine plus tenofovir alafenamide; daclatasvir; efavirenz plus emtricitabine plus tenofovir disoproxil; emtricitabine plus rilpivirine plus tenofovir alafeEvolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapyjournal article10.1111/jvh.13502337592902-s2.0-85103427501